Allspring Global Investments Holdings LLC Has $17.72 Million Holdings in Pfizer Inc. $PFE

Allspring Global Investments Holdings LLC decreased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 28.1% in the 1st quarter, Holdings Channel reports. The fund owned 620,597 shares of the biopharmaceutical company’s stock after selling 241,954 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Pfizer were worth $17,718,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in PFE. Evolution Wealth Management Inc. boosted its stake in shares of Pfizer by 132.2% in the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 566 shares during the last quarter. Horizon Financial Services LLC raised its stake in Pfizer by 174.8% during the fourth quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 645 shares during the last quarter. Godfrey Financial Associates Inc. acquired a new position in Pfizer in the fourth quarter valued at $26,000. YANKCOM Partnership acquired a new position in Pfizer in the fourth quarter valued at $28,000. Finally, HFM Investment Advisors LLC boosted its position in Pfizer by 61.0% during the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 427 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

PFE has been the subject of several recent analyst reports. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. Guggenheim cut their price target on Pfizer from $36.00 to $35.00 and set a “buy” rating on the stock in a report on Monday, July 13th. Weiss Ratings upgraded shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, May 6th. Royal Bank Of Canada upgraded shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 target price on the stock in a research report on Tuesday, June 9th. Finally, UBS Group reissued a “neutral” rating and set a $27.00 target price on shares of Pfizer in a research note on Wednesday, May 27th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $28.50.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer could benefit from strength in key non-oncology drugs, with Eliquis and Vyndaqel expected to post better Q2 sales, which may help offset declines elsewhere in the portfolio. What to Watch in Pfizer’s Non-Oncology Portfolio This Earnings Season
• Positive Sentiment: Pfizer is drawing interest as a potential winner in the large weight-loss drug market, supporting longer-term growth expectations if it can compete successfully. Could Pfizer Ultimately Be the Biggest Winner in the $100 Billion Weight-Loss Market?
• Neutral Sentiment: Pfizer remains one of the more watched healthcare names among investors, suggesting the stock may see ongoing trading interest ahead of earnings and new updates. Is Trending Stock Pfizer Inc. (PFE) a Buy Now?
• Neutral Sentiment: Recent commentary compared Pfizer with other sub-$50 stocks, but the note was mainly a general screening piece rather than a company-specific catalyst. 1 Stock Under $50 to Target This Week and 2 We Question
• Negative Sentiment: Pfizer faces new international patent lawsuits from Arbutus Biopharma and Genevant Sciences over its mRNA COVID-19 vaccines, creating potential damage claims and injunction risk. Pfizer (PFE) Faces New International Patent Lawsuits Over Covid 19 Vaccine
• Negative Sentiment: COVID-related product sales are expected to decline, which may weigh on quarterly results and reinforce concerns about shrinking pandemic-era revenue streams. What to Watch in Pfizer’s Non-Oncology Portfolio This Earnings Season

Pfizer Stock Performance

NYSE PFE opened at $24.91 on Wednesday. The company has a fifty day moving average price of $25.17 and a 200-day moving average price of $26.18. The firm has a market cap of $141.97 billion, a price-to-earnings ratio of 19.02 and a beta of 0.35. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. Pfizer Inc. has a 1 year low of $23.11 and a 1 year high of $28.75.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The business had revenue of $14.45 billion for the quarter, compared to analysts’ expectations of $13.84 billion. During the same period in the previous year, the company earned $0.92 earnings per share. The firm’s revenue for the quarter was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities research analysts predict that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, July 24th. This represents a $1.72 annualized dividend and a yield of 6.9%. Pfizer’s dividend payout ratio is presently 131.30%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.